Natera's robust financial performance, driven by strong growth in its Women’s Health and Oncology segments, justifies its recent stock price surge and positive outlook. The company’s strategic ...
Business Wire: Natera and MyOme Announce Launch of iPRS™ for Breast Cancer Risk Assessment
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, and MyOme, a leading clinical whole genome analysis and polygenic risk modeling ...
Natera and MyOme Announce Launch of iPRS™ for Breast Cancer Risk Assessment
Natera, Inc. is a diagnostic company focusing on cfDNA tests in women's health, organ health, and oncology. Natera's MRD test, Signatera, demonstrated strong growth, with a 64% increase in processed ...
Genetic testing company Natera (NASDAQ:NTRA). reported Q2 CY2025 results , with sales up 32.2% year on year to $546.6 million. The company’s full-year revenue guidance of $2.06 billion at the midpoint ...
Business Wire: Natera Publishes Clinical Validation of Latitude™ Tissue-Free MRD Test in Colorectal Cancer
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the publication in npj Precision Oncology of the validation study ...
Natera Publishes Clinical Validation of Latitude™ Tissue-Free MRD Test in Colorectal Cancer
Nasdaq: Natera Launches Fetal Focus™: A Noninvasive Prenatal Test for Inherited Conditions
AUSTIN, Texas--(BUSINESS WIRE)-- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing and precision medicine, today announced the launch of Fetal Focus, a noninvasive prenatal ...
Morningstar: MyOme Debuts Zenith™ Portfolio with Natera and Launches Long-Read Methylation Analysis at ACMG 2026
In a major step toward expanding patient access, MyOme is highlighting its strategic partnership with Natera (NASDAQ: NTRA) to launch Zenith™ powered by MyOme. Zenith is a premium exome and genome ...